ASPIRING

Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe

Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING) aims to determine if antiplatelet monotherapy is of overall net benefit in reducing the incidence of major adverse cardiovascular events compared to avoiding antiplatelet therapy for adults with a history of spontaneous ICH.

It is an investigator-led, multicentre, prospective, randomised, open-label, blinded outcome (PROBE), parallel-group clinical trial.

ASPIRING is currently in a multicentre pilot phase in China and Australia. More information can be found on the ASPIRING website.